Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post by Liam Harris on X, adding:
“Trying to reconcile adjuvant success with first line failure.
Is it that when CDK4/6 inhibition dominates the treatment effect in endocrine-sensitive disease, swapping the endocrine backbone doesn’t meaningfully change outcomes? Would Lidera have been negative if CDK 4/6 was added?”
Quoting Liam Harris on X:
“Mechanism looks promising on paper, but clinical validation tells a different story.
Waiting on SERENA-4 to see if the class delivers.”
Other articles featuring Sarah Sammons on OncoDaily.